CA2788223A1 - Procede de prevention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimetique de l'apolipoproteine-a1 (apoa1) - Google Patents

Procede de prevention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimetique de l'apolipoproteine-a1 (apoa1) Download PDF

Info

Publication number
CA2788223A1
CA2788223A1 CA2788223A CA2788223A CA2788223A1 CA 2788223 A1 CA2788223 A1 CA 2788223A1 CA 2788223 A CA2788223 A CA 2788223A CA 2788223 A CA2788223 A CA 2788223A CA 2788223 A1 CA2788223 A1 CA 2788223A1
Authority
CA
Canada
Prior art keywords
diastolic dysfunction
subject
apoa1
mimetic peptide
controlling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2788223A
Other languages
English (en)
Inventor
Jean-Claude Tardif
David Busseuil
Eric Rheaume
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Cardiologie de Montreal
Original Assignee
Institut de Cardiologie de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Cardiologie de Montreal filed Critical Institut de Cardiologie de Montreal
Publication of CA2788223A1 publication Critical patent/CA2788223A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2788223A 2009-01-23 2010-01-25 Procede de prevention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimetique de l'apolipoproteine-a1 (apoa1) Abandoned CA2788223A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20205109P 2009-01-23 2009-01-23
US61/202,051 2009-01-23
US20219109P 2009-02-05 2009-02-05
US61/202,191 2009-02-05
PCT/CA2010/000108 WO2010083611A1 (fr) 2009-01-23 2010-01-25 Procédé de prévention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimétique de l'apolipoprotéine-a1 (apoa1)

Publications (1)

Publication Number Publication Date
CA2788223A1 true CA2788223A1 (fr) 2010-07-29

Family

ID=42355467

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2788223A Abandoned CA2788223A1 (fr) 2009-01-23 2010-01-25 Procede de prevention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimetique de l'apolipoproteine-a1 (apoa1)

Country Status (3)

Country Link
EP (1) EP2389189A4 (fr)
CA (1) CA2788223A1 (fr)
WO (1) WO2010083611A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478592B2 (en) 2011-08-31 2019-11-19 Becton, Dickinson And Company Systems and methods to increase rigidity and snag-resistance of catheter tip

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2396017E (pt) 2009-02-16 2015-10-22 Cerenis Therapeutics Holding Sa Miméticos da apolipoproteína a-i
CA2806606A1 (fr) * 2010-07-28 2012-02-02 Institut De Cardiologie De Montreal Compositions pharmaceutiques pour le traitement du dysfonctionnement diastolique ventriculaire gauche comprenant un complexe de peptides/phospholipides d'apolipoproteines
TW201215394A (en) 2010-08-30 2012-04-16 Hoffmann La Roche Tetranectin-apolipoprotein A-I, lipid particles containing it and its use
CA2838070A1 (fr) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Proteine hybride raccourcie tetranectine-apolipoproteine a-i, particule lipidique la contenant, et utilisations associees

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
MXPA01009893A (es) 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
EP2537526A1 (fr) * 2006-06-01 2012-12-26 Institut de Cardiologie de Montréal Méthode et composé pour le traitement des sténoses valvulaires

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478592B2 (en) 2011-08-31 2019-11-19 Becton, Dickinson And Company Systems and methods to increase rigidity and snag-resistance of catheter tip

Also Published As

Publication number Publication date
WO2010083611A1 (fr) 2010-07-29
EP2389189A4 (fr) 2012-12-19
EP2389189A1 (fr) 2011-11-30

Similar Documents

Publication Publication Date Title
US20180203025A1 (en) Hdl therapy markers
JP5317691B2 (ja) 荷電リポタンパク質複合体およびその使用
ES2717455T3 (es) Complejos de lipoproteínas y fabricación y usos de los mismos
JP5954736B2 (ja) 難治性炎症性腸疾患の予防又は治療方法
S Getz et al. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders
US8163699B2 (en) Method for the treatment of valvular disease
JP2008534487A5 (fr)
JP2015526458A (ja) 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤
CA2788223A1 (fr) Procede de prevention et de traitement d'un dysfonctionnement diastolique au moyen d'un complexe peptide/phospholipide mimetique de l'apolipoproteine-a1 (apoa1)
TW200808335A (en) Methods for the treatment of macular degeneration and related eye conditions
Verdier et al. Targeting high-density lipoproteins: update on a promising therapy
Zhang et al. Calcium desensitizer catechin reverses diastolic dysfunction in mice with restrictive cardiomyopathy
CN106232141A (zh) 针对由给予类固醇诱发的生长不足的药物
Lehrke et al. Cardiovascular effects of incretin-based therapies
CN105050614B (zh) 刺激胆固醇流出的具有降低的毒性的肽
JP2022064986A (ja) Ｌｌｐ２ａ－ビスホスホネート化合物を用いて骨壊死を処置する方法
Brousseau Emerging role of high-density lipoprotein in the prevention of cardiovascular disease
US20070197442A1 (en) Methods for the Treatment of Macular Degeneration and Related Eye Conditions
WO2017120568A1 (fr) Compositions de peptides mimétiques de l'apoe
US20150150939A1 (en) Apolipoprotein Mixtures
JP2019520341A (ja) 代謝疾患を治療する組成物と方法
Hutt et al. Medical Treatment Strategies for Hypertrophic Cardiomyopathy
WO2019199976A1 (fr) Compositions peptidiques mimétiques d'apoe
WO2018190896A1 (fr) Compositions de peptides mimétiques de l'apoe
Claudia Targeting Microsomal Triglyceride Transfer Protein for the treatment of Homozygous Familial Hypercholesterolaemia

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20160126